A 2-Year Pilot Trial of Continuous Subcutaneous Insulin Infusion Versus Intensive Insulin Therapy in Patients with Newly Diagnosed Type 1 Diabetes (IMDIAB 8)

Paolo Pozzilli, Antonino Crinó, Riccardo Schiaffini, Silvia Manfrini, Elvira Fioriti, Giusy Coppolino, Dario Pitocco, Natalia Visalli, Stefania Corbi, Sabrina Spera, Concetta Suraci, Marco Cervoni, Maria C. Matteoli, I. Patrizia Patera, Giovanni Ghirlanda, Luciana Valente, Chiara Guglielmi, Giuseppina Beretta Anguissola, Flavia Costanza, Anna Lisa Montemari & 6 others Anna Cantagallo, Giancarlo De Mattia, Maria R Cassone Faldetta, Maria L Manca Bitti, Giovanni Marietti, Carla Bizzarri

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

In a pilot study, the metabolic effects of continuous subcutaneous insulin infusion (CSII) versus intensive subcutaneous insulin therapy (ISIT) started at diagnosis in patients with Type 1 diabetes and continued for a 2-year period were evaluated and compared. Twenty-three patients (between 12 and 35 years old, mean ± SD 18.4 ± 9 years) were randomized into two treatment groups (CSII vs. ISIT), and both received supplemental nicotinamide (NA), 25 mg/kg of body weight. CSII was started immediately after admission to the hospital. Parameters of metabolic control [insulin dose, hemoglobin A 1c (HbA1c), and C-peptide] were evaluated for a 2-year follow-up period. Data are presented for a total of 19 patients who remained in the study for its duration. Two years after diagnosis, mean ± SD HbA 1c was 6.3 ± 0.5% and 6.2 ± 0.3% for the CSII and ISIT groups, respectively (p = not significant). Compared with baseline values, an increase of baseline C-peptide of 38% for the CSII group and 27% for the ISIT group was observed; however, the difference between the groups was not significant. The insulin requirement for the entire duration of the study, but not at entry and 3 months, was significantly higher in CSII compared with ISIT patients (0.62 ± 0.4 IU/kg/day vs. 0.3 ± 0.4 IU/kg/day, respectively; p <0.01). After trial completion patients on CSII continued with this mode of therapy. Implementation of CSII as well as ISIT at diagnosis of Type 1 diabetes and continuation for 2 years thereafter achieved similar and optimal metabolic control, but more insulin was required with the CSII group. Both types of intensive insulin therapy combined with NA are able to preserve C-peptide secretion or even increase baseline levels for up to 2 years after diagnosis.

Original languageEnglish
Pages (from-to)965-974
Number of pages10
JournalDiabetes Technology and Therapeutics
Volume5
Issue number6
DOIs
Publication statusPublished - 2003

Fingerprint

Subcutaneous Infusions
Medical problems
Type 1 Diabetes Mellitus
Insulin
Therapeutics
C-Peptide
Niacinamide
Group Psychotherapy
Hemoglobin C
Hemoglobin A

ASJC Scopus subject areas

  • Endocrinology
  • Medicine (miscellaneous)
  • Clinical Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

A 2-Year Pilot Trial of Continuous Subcutaneous Insulin Infusion Versus Intensive Insulin Therapy in Patients with Newly Diagnosed Type 1 Diabetes (IMDIAB 8). / Pozzilli, Paolo; Crinó, Antonino; Schiaffini, Riccardo; Manfrini, Silvia; Fioriti, Elvira; Coppolino, Giusy; Pitocco, Dario; Visalli, Natalia; Corbi, Stefania; Spera, Sabrina; Suraci, Concetta; Cervoni, Marco; Matteoli, Maria C.; Patera, I. Patrizia; Ghirlanda, Giovanni; Valente, Luciana; Guglielmi, Chiara; Anguissola, Giuseppina Beretta; Costanza, Flavia; Montemari, Anna Lisa; Cantagallo, Anna; De Mattia, Giancarlo; Faldetta, Maria R Cassone; Bitti, Maria L Manca; Marietti, Giovanni; Bizzarri, Carla.

In: Diabetes Technology and Therapeutics, Vol. 5, No. 6, 2003, p. 965-974.

Research output: Contribution to journalArticle

Pozzilli, P, Crinó, A, Schiaffini, R, Manfrini, S, Fioriti, E, Coppolino, G, Pitocco, D, Visalli, N, Corbi, S, Spera, S, Suraci, C, Cervoni, M, Matteoli, MC, Patera, IP, Ghirlanda, G, Valente, L, Guglielmi, C, Anguissola, GB, Costanza, F, Montemari, AL, Cantagallo, A, De Mattia, G, Faldetta, MRC, Bitti, MLM, Marietti, G & Bizzarri, C 2003, 'A 2-Year Pilot Trial of Continuous Subcutaneous Insulin Infusion Versus Intensive Insulin Therapy in Patients with Newly Diagnosed Type 1 Diabetes (IMDIAB 8)', Diabetes Technology and Therapeutics, vol. 5, no. 6, pp. 965-974. https://doi.org/10.1089/152091503322641006
Pozzilli, Paolo ; Crinó, Antonino ; Schiaffini, Riccardo ; Manfrini, Silvia ; Fioriti, Elvira ; Coppolino, Giusy ; Pitocco, Dario ; Visalli, Natalia ; Corbi, Stefania ; Spera, Sabrina ; Suraci, Concetta ; Cervoni, Marco ; Matteoli, Maria C. ; Patera, I. Patrizia ; Ghirlanda, Giovanni ; Valente, Luciana ; Guglielmi, Chiara ; Anguissola, Giuseppina Beretta ; Costanza, Flavia ; Montemari, Anna Lisa ; Cantagallo, Anna ; De Mattia, Giancarlo ; Faldetta, Maria R Cassone ; Bitti, Maria L Manca ; Marietti, Giovanni ; Bizzarri, Carla. / A 2-Year Pilot Trial of Continuous Subcutaneous Insulin Infusion Versus Intensive Insulin Therapy in Patients with Newly Diagnosed Type 1 Diabetes (IMDIAB 8). In: Diabetes Technology and Therapeutics. 2003 ; Vol. 5, No. 6. pp. 965-974.
@article{ddc1bafe90c148f4a79e65d3c58eb567,
title = "A 2-Year Pilot Trial of Continuous Subcutaneous Insulin Infusion Versus Intensive Insulin Therapy in Patients with Newly Diagnosed Type 1 Diabetes (IMDIAB 8)",
abstract = "In a pilot study, the metabolic effects of continuous subcutaneous insulin infusion (CSII) versus intensive subcutaneous insulin therapy (ISIT) started at diagnosis in patients with Type 1 diabetes and continued for a 2-year period were evaluated and compared. Twenty-three patients (between 12 and 35 years old, mean ± SD 18.4 ± 9 years) were randomized into two treatment groups (CSII vs. ISIT), and both received supplemental nicotinamide (NA), 25 mg/kg of body weight. CSII was started immediately after admission to the hospital. Parameters of metabolic control [insulin dose, hemoglobin A 1c (HbA1c), and C-peptide] were evaluated for a 2-year follow-up period. Data are presented for a total of 19 patients who remained in the study for its duration. Two years after diagnosis, mean ± SD HbA 1c was 6.3 ± 0.5{\%} and 6.2 ± 0.3{\%} for the CSII and ISIT groups, respectively (p = not significant). Compared with baseline values, an increase of baseline C-peptide of 38{\%} for the CSII group and 27{\%} for the ISIT group was observed; however, the difference between the groups was not significant. The insulin requirement for the entire duration of the study, but not at entry and 3 months, was significantly higher in CSII compared with ISIT patients (0.62 ± 0.4 IU/kg/day vs. 0.3 ± 0.4 IU/kg/day, respectively; p <0.01). After trial completion patients on CSII continued with this mode of therapy. Implementation of CSII as well as ISIT at diagnosis of Type 1 diabetes and continuation for 2 years thereafter achieved similar and optimal metabolic control, but more insulin was required with the CSII group. Both types of intensive insulin therapy combined with NA are able to preserve C-peptide secretion or even increase baseline levels for up to 2 years after diagnosis.",
author = "Paolo Pozzilli and Antonino Crin{\'o} and Riccardo Schiaffini and Silvia Manfrini and Elvira Fioriti and Giusy Coppolino and Dario Pitocco and Natalia Visalli and Stefania Corbi and Sabrina Spera and Concetta Suraci and Marco Cervoni and Matteoli, {Maria C.} and Patera, {I. Patrizia} and Giovanni Ghirlanda and Luciana Valente and Chiara Guglielmi and Anguissola, {Giuseppina Beretta} and Flavia Costanza and Montemari, {Anna Lisa} and Anna Cantagallo and {De Mattia}, Giancarlo and Faldetta, {Maria R Cassone} and Bitti, {Maria L Manca} and Giovanni Marietti and Carla Bizzarri",
year = "2003",
doi = "10.1089/152091503322641006",
language = "English",
volume = "5",
pages = "965--974",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - A 2-Year Pilot Trial of Continuous Subcutaneous Insulin Infusion Versus Intensive Insulin Therapy in Patients with Newly Diagnosed Type 1 Diabetes (IMDIAB 8)

AU - Pozzilli, Paolo

AU - Crinó, Antonino

AU - Schiaffini, Riccardo

AU - Manfrini, Silvia

AU - Fioriti, Elvira

AU - Coppolino, Giusy

AU - Pitocco, Dario

AU - Visalli, Natalia

AU - Corbi, Stefania

AU - Spera, Sabrina

AU - Suraci, Concetta

AU - Cervoni, Marco

AU - Matteoli, Maria C.

AU - Patera, I. Patrizia

AU - Ghirlanda, Giovanni

AU - Valente, Luciana

AU - Guglielmi, Chiara

AU - Anguissola, Giuseppina Beretta

AU - Costanza, Flavia

AU - Montemari, Anna Lisa

AU - Cantagallo, Anna

AU - De Mattia, Giancarlo

AU - Faldetta, Maria R Cassone

AU - Bitti, Maria L Manca

AU - Marietti, Giovanni

AU - Bizzarri, Carla

PY - 2003

Y1 - 2003

N2 - In a pilot study, the metabolic effects of continuous subcutaneous insulin infusion (CSII) versus intensive subcutaneous insulin therapy (ISIT) started at diagnosis in patients with Type 1 diabetes and continued for a 2-year period were evaluated and compared. Twenty-three patients (between 12 and 35 years old, mean ± SD 18.4 ± 9 years) were randomized into two treatment groups (CSII vs. ISIT), and both received supplemental nicotinamide (NA), 25 mg/kg of body weight. CSII was started immediately after admission to the hospital. Parameters of metabolic control [insulin dose, hemoglobin A 1c (HbA1c), and C-peptide] were evaluated for a 2-year follow-up period. Data are presented for a total of 19 patients who remained in the study for its duration. Two years after diagnosis, mean ± SD HbA 1c was 6.3 ± 0.5% and 6.2 ± 0.3% for the CSII and ISIT groups, respectively (p = not significant). Compared with baseline values, an increase of baseline C-peptide of 38% for the CSII group and 27% for the ISIT group was observed; however, the difference between the groups was not significant. The insulin requirement for the entire duration of the study, but not at entry and 3 months, was significantly higher in CSII compared with ISIT patients (0.62 ± 0.4 IU/kg/day vs. 0.3 ± 0.4 IU/kg/day, respectively; p <0.01). After trial completion patients on CSII continued with this mode of therapy. Implementation of CSII as well as ISIT at diagnosis of Type 1 diabetes and continuation for 2 years thereafter achieved similar and optimal metabolic control, but more insulin was required with the CSII group. Both types of intensive insulin therapy combined with NA are able to preserve C-peptide secretion or even increase baseline levels for up to 2 years after diagnosis.

AB - In a pilot study, the metabolic effects of continuous subcutaneous insulin infusion (CSII) versus intensive subcutaneous insulin therapy (ISIT) started at diagnosis in patients with Type 1 diabetes and continued for a 2-year period were evaluated and compared. Twenty-three patients (between 12 and 35 years old, mean ± SD 18.4 ± 9 years) were randomized into two treatment groups (CSII vs. ISIT), and both received supplemental nicotinamide (NA), 25 mg/kg of body weight. CSII was started immediately after admission to the hospital. Parameters of metabolic control [insulin dose, hemoglobin A 1c (HbA1c), and C-peptide] were evaluated for a 2-year follow-up period. Data are presented for a total of 19 patients who remained in the study for its duration. Two years after diagnosis, mean ± SD HbA 1c was 6.3 ± 0.5% and 6.2 ± 0.3% for the CSII and ISIT groups, respectively (p = not significant). Compared with baseline values, an increase of baseline C-peptide of 38% for the CSII group and 27% for the ISIT group was observed; however, the difference between the groups was not significant. The insulin requirement for the entire duration of the study, but not at entry and 3 months, was significantly higher in CSII compared with ISIT patients (0.62 ± 0.4 IU/kg/day vs. 0.3 ± 0.4 IU/kg/day, respectively; p <0.01). After trial completion patients on CSII continued with this mode of therapy. Implementation of CSII as well as ISIT at diagnosis of Type 1 diabetes and continuation for 2 years thereafter achieved similar and optimal metabolic control, but more insulin was required with the CSII group. Both types of intensive insulin therapy combined with NA are able to preserve C-peptide secretion or even increase baseline levels for up to 2 years after diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=0346993686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346993686&partnerID=8YFLogxK

U2 - 10.1089/152091503322641006

DO - 10.1089/152091503322641006

M3 - Article

VL - 5

SP - 965

EP - 974

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 6

ER -